News ) announced that in a phase I/II clinical trial, substitution of its investigational drug Pixantrone for Doxorubicin in CHOP (Cyclophosphamide, Doxorubicin, Oncovin and Prednisone) chemotherapy regimen produced high rates of complete remissions and long-term disease free survival in patients with relapsed/refractory aggressive non-Hodgkin’s lymphoma who previously failed the frontline CHOP therapy.
The results were published in the April 2011 edition of the peer reviewed journal, Leukemia amp; Lymphoma.According to the company, the study enrolled 35 patients in the phase I portion of the trial and 30 patients in the phase II portion of the trial.
A major tumor response was reported for 80% and 73% of patients in phase I and II respectively, with 57% and 47% of the patients achieving a co…